🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "major milestone" in the battle against drug-resistant strains of the bacteria, according to health experts.

A Worldwide Health Concern

Gonorrhoea infections are on the rise globally, with figures suggesting more than 82 million infections per year. Notably increased rates are reported in the African continent and countries within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. Across England, cases have reached a all-time high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an critical and opportune advancement in the reality of growing infection rates, escalating drug resistance and the very limited therapeutic options at this time.”

Public health authorities are increasingly worried about the rise in drug-resistant strains. The World Health Organization has listed it as a "critical concern". Recent surveillance found that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Drugs Secure Clearance

Zoliflodacin, also known as Nuzolvence, was approved by the US FDA in December for treating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Researchers believe that focused deployment of this new drug will help delay the spread of drug resistance.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, gained clearance in concurrent days. This drug, which is employed against urinary tract infections, was demonstrated in studies to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment was the result of a innovative non-profit model for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to develop it.

“This authorization signifies a huge turning point in the therapy of highly resistant gonorrhoea, which until now has been evolving faster than medical innovation.”

Testing Outcomes and Worldwide Availability

As per results detailed in a prominent scientific publication, zoliflodacin cured the vast majority of uncomplicated infections. This places it at an comparable level with the existing first-line therapy, which involves a dual-drug approach. The research enrolled nearly 1,000 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the authority to register and commercialise the drug in a wide range of low-income and middle-income countries.

Medical professionals on the front lines have voiced hope. Access to a easy-to-administer therapy like this is described as a "revolutionary step" for public health efforts. This is considered crucial to alleviate the strain of the infection for individuals and to stop the proliferation of untreatable gonorrhoea globally.